Brief: Clene Announces Additional Cnm-Au8 Biomarker Data Supporting Potential NDA Filing For Upcoming In-Person FDA Meeting
12/01/2026 13:36
Jan 12 (Reuters) - Clene Inc CLNN.O: CLENE ANNOUNCES ADDITIONAL CNM-AU8 BIOMARKER DATA SUPPORTING POTENTIAL NDA FILING FOR UPCOMING IN-PERSON FDA MEETING CLENE INC - FDA GRANTS IN-PERSON TYPE C MEETING FOR CNM-AU8 POTENTIAL NDA FILING IN Q1 2026 Source text: ID:nGNX1MdKT1 Further company coverage: CLNN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs